|
| 36511802 | NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. | Cancer Discov | 2023 |
| 37743366 | Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. | Nat Cancer | 2023 |
| 37587872 | Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. | EMBO Mol Med | 2023 |
| 37814012 | Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. | Nat Cancer | 2023 |
| 37410972 | Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel <i>SNX8-BRAF</i> Gene Fusion. | JCO Precis Oncol | 2023 |
| 36511802 | NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. | Cancer Discov | 2023 |
| 37587872 | Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. | EMBO Mol Med | 2023 |
| 37743366 | Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. | Nat Cancer | 2023 |
| 37814012 | Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. | Nat Cancer | 2023 |
| 37410972 | Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel <i>SNX8-BRAF</i> Gene Fusion. | JCO Precis Oncol | 2023 |
| 34907086 | Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. | Mol Cancer Ther | 2022 |
| 36307212 | Discovery and functional characterization of the oncogenicity and targetability of a novel <i>NOTCH1-ROS1</i> gene fusion in pediatric angiosarcoma. | Cold Spring Harb Mol Case Stud | 2022 |
| 35483883 | Corrigendum: Functional impact and targetability of <i>PI3KCA</i>, <i>GNAS</i>, and <i>PTEN</i> mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. | Cold Spring Harb Mol Case Stud | 2022 |
| 34907086 | Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors. | Mol Cancer Ther | 2022 |
| 35149545 | MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. | Mol Cancer Res | 2022 |
| 35483883 | Corrigendum: Functional impact and targetability of <i>PI3KCA</i>, <i>GNAS</i>, and <i>PTEN</i> mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. | Cold Spring Harb Mol Case Stud | 2022 |
| 36307212 | Discovery and functional characterization of the oncogenicity and targetability of a novel <i>NOTCH1-ROS1</i> gene fusion in pediatric angiosarcoma. | Cold Spring Harb Mol Case Stud | 2022 |
| 35149545 | MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer. | Mol Cancer Res | 2022 |
| 32760015 | ROS1-dependent cancers - biology, diagnostics and therapeutics. | Nat Rev Clin Oncol | 2021 |
| 34036664 | GAB1-ABL1 fusions in tumors that have histologic overlap with NTRK-rearranged spindle cell tumors. | Genes Chromosomes Cancer | 2021 |
| 34303840 | A targeted combinatorial therapy for Ewing's sarcoma. | Nanomedicine | 2021 |
| 32760015 | ROS1-dependent cancers - biology, diagnostics and therapeutics. | Nat Rev Clin Oncol | 2021 |
| 33432937 | A Broccoli aptamer chimera yields a fluorescent K<sup>+</sup> sensor spanning physiological concentrations. | Chem Commun (Camb) | 2021 |
| 34683845 | Discovery and Validation of a Compound to Target Ewing's Sarcoma. | Pharmaceutics | 2021 |
| 34429303 | Mechanisms of targeted therapy resistance in a pediatric glioma driven by <i>ETV6-NTRK3</i> fusion. | Cold Spring Harb Mol Case Stud | 2021 |
| 34429303 | Mechanisms of targeted therapy resistance in a pediatric glioma driven by <i>ETV6-NTRK3</i> fusion. | Cold Spring Harb Mol Case Stud | 2021 |
| 34683845 | Discovery and Validation of a Compound to Target Ewing's Sarcoma. | Pharmaceutics | 2021 |
| 34303840 | A targeted combinatorial therapy for Ewing's sarcoma. | Nanomedicine | 2021 |
| 34036664 | GAB1-ABL1 fusions in tumors that have histologic overlap with NTRK-rearranged spindle cell tumors. | Genes Chromosomes Cancer | 2021 |
| 33432937 | A Broccoli aptamer chimera yields a fluorescent K<sup>+</sup> sensor spanning physiological concentrations. | Chem Commun (Camb) | 2021 |
| 32315394 | Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. | Blood | 2020 |
| 31911548 | Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i>-Mutant Lung Cancer. | Clin Cancer Res | 2020 |
| 32315394 | Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. | Blood | 2020 |
| 32016232 | Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli. | Chem Commun (Camb) | 2020 |
| 32122926 | MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions. | Clin Cancer Res | 2020 |
| 32238360 | Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. | Cancer Discov | 2020 |
| 33318047 | RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation. | Dis Model Mech | 2020 |
| 33328556 | NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. | Commun Biol | 2020 |
| 32016232 | Subtle sequence variations alter tripartite complex kinetics and G-quadruplex dynamics in RNA aptamer Broccoli. | Chem Commun (Camb) | 2020 |
| 31911548 | Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i>-Mutant Lung Cancer. | Clin Cancer Res | 2020 |
| 33328556 | NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. | Commun Biol | 2020 |
| 33318047 | RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation. | Dis Model Mech | 2020 |
| 32122926 | MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions. | Clin Cancer Res | 2020 |
| 32238360 | Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. | Cancer Discov | 2020 |
| 30518629 | Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma. | Mol Cancer Res | 2019 |
| 31551508 | Revisiting NTRKs as an emerging oncogene in hematological malignancies. | Leukemia | 2019 |
| 30518629 | Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma. | Mol Cancer Res | 2019 |
| 31037281 | A ribose modification of Spinach aptamer accelerates lead(ii) cation association in vitro. | Chem Commun (Camb) | 2019 |
| 30899438 | A blast from the past: <i>ROS1</i> on the brain. | Oncotarget | 2019 |
| 31551508 | Revisiting NTRKs as an emerging oncogene in hematological malignancies. | Leukemia | 2019 |